Novel non-ATP competitive small molecules targeting the CK2 α/β interface
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Increased CK2 levels are prevalent in many cancers. Combined with the critical role CK2 plays in many cell-signaling pathways, this makes it a prime target for down regulation to fight tumour growth. Herein, we report a fragment-based approach to inhibiting the interaction between CK2α and CK2β at the α-β interface of the holoenzyme. A fragment, CAM187, with an IC50 of 44 μM and a molecular weight of only 257 gmol-1 has been identified as the most promising compound. Importantly, the lead fragment only bound at the interface and was not observed in the ATP binding site of the protein when co-crystallised with CK2α. The fragment-like molecules discovered in this study represent unique scaffolds to CK2 inhibition and leave room for further optimisation.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
1464-3391
Volume Title
Publisher
Publisher DOI
Sponsorship
Wellcome Trust (107714/Z/15/Z)
Engineering and Physical Sciences Research Council (EP/J016012/1)
Engineering and Physical Sciences Research Council (EP/P020291/1)
Wellcome Trust (090340/Z/09/Z)
European Research Council (279337)